Non-Hodgkin Lymphoma

Treatment with KTE-C19 demonstrated an objective response rate of 79% and a complete remission rate of 52% for patients with aggressive, chemorefractory non-Hodgkin's lymphoma.

A supplemental new drug application has been submitted to the FDA for the use of ibrutinib as a treatment for patients with marginal zone lymphoma.

Improved understanding of Waldenström's macroglobulinemia and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.